GoHealthGOCO.Q
GOCO.Q logo
Fair Value
US$2.75
Share price17 Jul
US$0.3487.7% undervalued intrinsic discount
Loading
1Y-94.39%
7D-7.81%

Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
31 Mar 25
Updated
17 Jul 26
Views
96
Not Invested

Last Update 17 Jul 26

Fair value Decreased 46%

GOCO.Q: Chapter 11 Restructuring Will Drive Future Upside After Nasdaq Delisting

Analysts have reduced their fair value estimate for GoHealth from $5.13 to $2.75 per share, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple.

What’s in the News for GoHealth

  • GoHealth and several affiliates filed voluntary petitions for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 7, 2026, with reported assets in the range of US$500 million to US$1b and liabilities in the range of US$1b to US$10b (Bankruptcy Filing).
  • The company subsequently filed a motion on June 7, 2026 for joint administration of the Chapter 11 cases of GoHealth and multiple affiliated entities, proposing GoHealth, Inc. as the lead debtor (Bankruptcy, Other).
  • On June 9, 2026 GoHealth received a Nasdaq notice stating that its Class A common stock will be delisted from Nasdaq, with trading set to be suspended at the opening of business on June 16, 2026 and a Form 25 NSE to be filed with the SEC. The company stated it does not intend to appeal the decision (Delisting, Nasdaq Notice).
  • Following the Nasdaq delisting determination, GoHealth indicated that its Class A common stock may be quoted on the OTCID Basic Market or another over the counter market. The company also highlighted that trading liquidity on such markets is typically more limited (Delisting, trading venue update).
  • GoHealth has been dropped from multiple major indices, including the Nasdaq Composite Index, various Russell indices such as the Russell 2000 Index and Russell 3000 Index, and the S&P TMI Index, following the Chapter 11 filing and related developments (Index constituent changes).

Valuation Changes for GoHealth

  • Fair Value: Reduced from $5.13 to $2.75 per share, signaling a materially lower valuation estimate for GoHealth.
  • Discount Rate: Unchanged at 12.46%, indicating the same assumed risk profile in the updated analysis.
  • Revenue Growth: Adjusted from 64.53% to 59.15%, reflecting slightly lower projected growth in dollar revenue.
  • Net Profit Margin: Revised from 11.06% to 11.10%, representing a very small upward change in expected profitability.
  • Future P/E: Lowered from 1.74x to 1.03x, indicating a significantly reduced valuation multiple applied to future earnings.
3 viewsusers have viewed this narrative update

Key Takeaways

  • Improved financial flexibility and strategic focus enable investment in technology, product expansion, and acquisitions, supporting future revenue growth and margin improvement.
  • Diversification into life insurance and enhanced tech capabilities boost efficiency, reduce earnings volatility, and position the company to capture greater market share.
  • Heavy reliance on debt, share dilution, and challenging acquisitions amid regulatory and market uncertainty heighten risks to sustainable growth and long-term value stability.

Catalysts

About GoHealth
    Operates as a health insurance marketplace and Medicare-focused digital health company in the United States.
What are the underlying business or industry changes driving this perspective?
  • The newly secured $115 million term loan facility, along with covenant relief and maturity extensions, grants GoHealth significant financial flexibility and removes immediate going concern issues, enabling proactive investment in technology, product growth, and M&A-positioning the company for revenue growth and improved net margins over the medium term.
  • The company's ability to actively pursue strategic acquisitions in a fragmented Medicare and senior health marketplace-with up to $250 million of lender-approved deal capacity and an empowered Transformation Committee-positions GoHealth to capture greater market share and drive scale-driven operating leverage, benefitting both revenue and margins.
  • Deployment and scaling of the GoHealth Protect (final expense/life insurance) product suite diversifies revenue sources beyond Medicare Advantage, reducing earnings volatility and creating new cross-sell opportunities-expected to support incremental revenue growth and margin stabilization as the digitalization of healthcare shopping accelerates.
  • Enhanced technology and data-driven supply/demand matching are enabling higher agent productivity and operational efficiency, which should allow for lower cost per acquisition and higher lead-to-policy conversion rates-supporting future earnings and margin expansion as consumer reliance on advisory platforms increases due to rising healthcare complexity.
  • GoHealth remains structurally levered to ongoing demographic aging and heightened regulatory/benefit disruption in core Medicare markets, creating sustained demand for unbiased, tech-enabled plan selection platforms-likely to translate into persistent customer acquisition opportunities and long-term top-line growth.
GoHealth Earnings and Revenue Growth

GoHealth Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming GoHealth's revenue will grow by 59.2% annually over the next 3 years.
  • Analysts are not forecasting that GoHealth will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate GoHealth's profit margin will increase from -192.3% to the average US Insurance industry of 11.1% in 3 years.
  • If GoHealth's profit margin were to converge on the industry average, you could expect earnings to reach $68.4 million (and earnings per share of $3.6) by about July 2029, up from -$293.9 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 1.1x on those 2029 earnings, up from -0.0x today. This future PE is lower than the current PE for the US Insurance industry at 12.0x.
  • Analysts expect the number of shares outstanding to grow by 4.37% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 12.46%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • GoHealth's recent issuance of significant equity to lenders as part of the new debt facility leads to share dilution, directly impacting per-share earnings and potentially limiting share price appreciation for existing shareholders despite operational improvements.
  • The company is undergoing an intangible asset impairment, indicative of prior overvaluation of assets or underperformance in acquired businesses; this raises concerns over GoHealth's ability to accurately forecast and deliver sustained value from acquisitions, increasing volatility and uncertainty in long-term earnings and revenue streams.
  • While GoHealth has secured a temporary covenant holiday and capital runway, its reliance on debt financing with high interest rates (SOFR + 550 bps) raises longer-term financial risk and higher interest expenses, which can compress net margins and reduce future profitability.
  • GoHealth's strategy to focus more intensely on industry consolidation and M&A, while potentially accretive, exposes it to substantial execution risk and integration challenges-if acquisitions fail to deliver expected synergies or results, this could hinder revenue growth and margin expansion.
  • The company's substantial pullback from Medicare Advantage activity in response to health plan uncertainty, along with ongoing regulatory and market disruptions, highlights its sensitivity to external factors (like plan benefit changes and regulatory shifts), which could further impact customer acquisition, retention, and revenue predictability going forward.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $2.75 for GoHealth based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.0, and the most bearish reporting a price target of just $1.5.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $615.9 million, earnings will come to $68.4 million, and it would be trading on a PE ratio of 1.1x, assuming you use a discount rate of 12.5%.
  • Given the current share price of $0.35, the analyst price target of $2.75 is 87.3% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on GoHealth?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$2.75
vs US$0.3487.7% undervalued intrinsic discount
PastFuture-233m1b2018202020222024202620282029Revenue US$649.1mEarnings US$72.1m
62%
Revenue growth
11.1%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on GoHealth

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Medium-low risk and fair value.

Market capUS$9.1m
PB2.6x
Estimated Growth41.7%
Dividend YieldN/A
Full analysis

CEO & management

Vijay Kotte
CEO
3.3yrs
CEO Tenure

Operates as a health insurance marketplace and Medicare-focused digital health company in the United States.